Format

Send to

Choose Destination
BMJ Case Rep. 2018 Jan 11;2018. pii: bcr-2017-221405. doi: 10.1136/bcr-2017-221405.

Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment.

Author information

1
Medicine, Washington University, Saint Louis, Missouri, USA.
2
Gastroenterology, Specialists in Gastroenterology, Saint Louis, MO, USA.
3
Biostatistics, Private Practice, Anchorage, Alaska, USA.
4
Gastrointestinal Department, Specialists in Gastroenterology, Saint Louis, Missouri, USA.
5
Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.

Abstract

A patient with severe postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS) received immunotherapy with low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIg) and antibiotic therapy for small intestinal bacterial overgrowth (SIBO). A dramatic and sustained response was documented. The utility of IVIg in autoimmune neuromuscular diseases has been published, but clinical experience with POTS is relatively unknown and has not been reported in MCAS. As a short-acting mu-opioid antagonist, LDN paradoxically increases endorphins which then bind to regulatory T cells which regulate T-lymphocyte and B-lymphocyte production and this reduces cytokine and antibody production. IVIg is emerging as a promising therapy for POTS. Diagnosis and treatment of SIBO in POTS is a new concept and appears to play an important role.

KEYWORDS:

clinical neurophysiology; drugs: gastrointestinal system; immunological products and vaccines; immunology; therapeutic indications

PMID:
29326369
PMCID:
PMC5778345
DOI:
10.1136/bcr-2017-221405
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center